Severe Atopic Dermatitis

The phase 3 JADE COMPARE trial met its co-primary efficacy endpoints in adults with moderate to severe atopic dermatitis. Results from the trial, which compared the use of the JAK1 inhibitor abrocitinib with placebo, will be submitted for presentation at a future conference, according to a press release from Pfizer.

Eli Lilly and Company and Incyte announced that baricitinib met its primary endpoint in the BREEZE-AD4 and BREEZE-AD5 studies in patients with moderate to severe atopic dermatitis, according to two press releases.

Children aged 6 to 11 years with severe atopic dermatitis assigned dupilumab and topical corticosteroids significantly improved in measures of overall disease severity, skin clearing, itching and health-related quality of life vs. topical corticosteroids alone in a phase 3 trial.